Alliance Global Partners analyst Matthew Cross maintained a Buy rating on Aptose Biosciences (APTO – Research Report) today and set a price target of $8.00. The company’s shares closed last Wednesday at $1.22, close to its 52-week low of $1.00.
According to TipRanks.com, Cross is a 3-star analyst with an average return of 4.4% and a 36.6% success rate. Cross covers the Healthcare sector, focusing on stocks such as TRACON Pharmaceuticals, Syros Pharmaceuticals, and Aldeyra Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aptose Biosciences with a $7.72 average price target, representing a 548.7% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a C$12.00 price target.
The company has a one-year high of $7.20 and a one-year low of $1.00. Currently, Aptose Biosciences has an average volume of 420.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
Read More on APTO: